4BASEBIO PLC (88Q.DE) Stock Price, Quote, News and Overview
FRA:88Q - Deutsche Boerse Ag - GB00BMCLYF79 - Common Stock - Currency: EUR
88Q.DE Quote, Performance and Key Statistics
FRA:88Q (3/7/2025, 7:00:00 PM)
13.3
0 (0%)
The current stock price of 88Q.DE is 13.3 EUR. In the past month the price decreased by -4.32%. In the past year, price increased by 52.87%.
88Q.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
| 1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
| AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
| 1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
| GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
| ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
| IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
| 1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
| 0QF.DE | MODERNA INC | N/A | 13.19B |
Related stock screener links
About 88Q.DE
Company Profile
4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is focused on life sciences and in particular the development of synthetic Deoxyribonucleic acid (DNA) and nanoparticles suitable for inclusion in, or delivery of, therapeutic payloads for cell and gene therapies and vaccines. The company is engaged in the development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The company is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads in patients. The company has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications.
Company Info
4BASEBIO PLC
25 Norman Way, Over
CAMBRIDGE GB
Employees: 101
Company Website: https://www.4basebio.com/
Investor Relations: http://www.4basebio.com/investors/
Phone: 441223967943
4BASEBIO PLC / 88Q.DE FAQ
What is the stock price of 4BASEBIO PLC today?
The current stock price of 88Q.DE is 13.3 EUR.
What is the ticker symbol for 4BASEBIO PLC stock?
The exchange symbol of 4BASEBIO PLC is 88Q and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 88Q.DE stock listed?
88Q.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for 4BASEBIO PLC stock?
9 analysts have analysed 88Q.DE and the average price target is 21.37 EUR. This implies a price increase of 60.66% is expected in the next year compared to the current price of 13.3. Check the 4BASEBIO PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is 4BASEBIO PLC worth?
4BASEBIO PLC (88Q.DE) has a market capitalization of 205.88M EUR. This makes 88Q.DE a Micro Cap stock.
How many employees does 4BASEBIO PLC have?
4BASEBIO PLC (88Q.DE) currently has 101 employees.
What are the support and resistance levels for 4BASEBIO PLC (88Q.DE) stock?
4BASEBIO PLC (88Q.DE) has a support level at 13.21 and a resistance level at 13.34. Check the full technical report for a detailed analysis of 88Q.DE support and resistance levels.
Is 4BASEBIO PLC (88Q.DE) expected to grow?
The Revenue of 4BASEBIO PLC (88Q.DE) is expected to grow by 200% in the next year. Check the estimates tab for more information on the 88Q.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy 4BASEBIO PLC (88Q.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of 88Q.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of 88Q.DE, evaluating the profitability, health, valuation and growth aspects
- 4BASEBIO PLC (88Q.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- 4BASEBIO PLC (88Q.DE) Sales and EPS estimates to see what analysts future expectations are.
- 4BASEBIO PLC (88Q.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- 4BASEBIO PLC (88Q.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- 4BASEBIO PLC (88Q.DE) Stock Chart to make your own analysis
- 4BASEBIO PLC (88Q.DE) Latest news and press-releases to stay up to date.
Does 4BASEBIO PLC (88Q.DE) stock pay dividends?
88Q.DE does not pay a dividend.
What is the Price/Earnings (PE) ratio of 4BASEBIO PLC (88Q.DE)?
4BASEBIO PLC (88Q.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.74).
88Q.DE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 88Q.DE. When comparing the yearly performance of all stocks, 88Q.DE is one of the better performing stocks in the market, outperforming 88.84% of all stocks.
88Q.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to 88Q.DE. 88Q.DE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
88Q.DE Financial Highlights
Over the last trailing twelve months 88Q.DE reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS decreased by -48.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.26% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
88Q.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to 88Q.DE. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -33.33% and a revenue growth 200% for 88Q.DE